{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:51:01Z","timestamp":1776423061057,"version":"3.51.2"},"reference-count":63,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bone metastases represent an uncommon but clinically significant complication in endocrine malignancies including differentiated thyroid cancer and neuroendocrine tumors. Although these malignancies typically follow an indolent course, the development of bone metastases is associated with a worse prognosis and increased risk of skeletal-related events. The optimal strategies for the prevention and management of bone metastases in these patients remain unclear and are largely extrapolated from studies in other solid tumors. This presents a unique clinical challenge as treatment decisions need to balance the prevention of skeletal-related events against the potential risks of prolonged antiresorptive therapy in patients expected to have a long survival time. This article reviews the clinical complexities involved in managing bone metastases in differentiated thyroid cancer and neuroendocrine tumors. The clinical cases presented highlight key considerations to guide clinical decision-making when treating these specific patient populations.<\/jats:p>","DOI":"10.1210\/jendso\/bvag065","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:34:07Z","timestamp":1774355647000},"source":"Crossref","is-referenced-by-count":0,"title":["Challenges in the management of bone metastases: focus on differentiated thyroid cancer and neuroendocrine tumors"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-1751","authenticated-orcid":false,"given":"Julie","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Stanford University School of Medicine , Stanford, CA 94305, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-4503","authenticated-orcid":false,"given":"Joy Y","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Stanford University School of Medicine , Stanford, CA 94305, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2026041705523867500_bvag065-B1","first-page":"1","article-title":"Quality of life issues in patients with bone metastases: a systematic review","volume":"32","author":"Rajeswaran","year":"2024","journal-title":"Support Care Cancer"},{"issue":"4","key":"2026041705523867500_bvag065-B2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1634\/theoncologist.2014-0328","article-title":"Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of Skeletal-related events in cancer patients with bone metastasis","volume":"20","author":"Wang","year":"2015","journal-title":"Oncologist"},{"issue":"3","key":"2026041705523867500_bvag065-B3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/cancers17030388","article-title":"Denosumab vs. Zoledronic acid for metastatic bone disease: a comprehensive systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Wajda","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"35","key":"2026041705523867500_bvag065-B4","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American society of clinical oncology\u2013cancer care Ontario focused guideline update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"2026041705523867500_bvag065-B5","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974-2013","volume":"317","author":"Lim","year":"2017","journal-title":"JAMA"},{"issue":"8","key":"2026041705523867500_bvag065-B6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"issue":"1","key":"2026041705523867500_bvag065-B7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/thy.2022.0353","article-title":"Disease-specific survival trends for patients presenting with differentiated thyroid cancer and distant metastases in the United States, 1992\u20132018","volume":"33","author":"Wilhelm","year":"2023","journal-title":"Thyroid"},{"issue":"4","key":"2026041705523867500_bvag065-B8","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1210\/jc.2016-3906","article-title":"Skeletal complications and mortality in thyroid cancer: a population-based study","volume":"102","author":"Choksi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"2026041705523867500_bvag065-B9","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.3390\/cancers15143557","article-title":"Osseous metastases in thyroid cancer: unveiling risk factors, disease outcomes, and treatment impact","volume":"15","author":"Khired","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2026041705523867500_bvag065-B10","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026041705523867500_bvag065-B11","first-page":"129","article-title":"Thyroid carcinoma with bone metastases: a prognostic factor study","volume":"2","author":"Wu","year":"2008","journal-title":"Clin Med Oncol"},{"key":"2026041705523867500_bvag065-B12","first-page":"598","article-title":"Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma","volume":"37","author":"Schlumberger","year":"1996","journal-title":"J Nucl Med"},{"issue":"10","key":"2026041705523867500_bvag065-B13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.eprac.2025.07.010","article-title":"Prognostic factors and survival outcomes in thyroid cancer patients with bone metastasis: insights from a population-based cohort study","volume":"31","author":"Zhao","year":"2025","journal-title":"Endocr Pract"},{"issue":"7","key":"2026041705523867500_bvag065-B14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/thy.2023.0709","article-title":"Survival prognostication in patients with differentiated thyroid cancer and distant metastases: a SEER population-based study","volume":"34","author":"Chen","year":"2024","journal-title":"Thyroid"},{"issue":"3","key":"2026041705523867500_bvag065-B15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1530\/EJE-16-0237","article-title":"Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma","volume":"175","author":"Choi","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026041705523867500_bvag065-B16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/hed.24655","article-title":"Systematic review of site distribution of bone metastases in differentiated thyroid cancer","volume":"39","author":"Osorio","year":"2017","journal-title":"Head Neck"},{"issue":"7","key":"2026041705523867500_bvag065-B17","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1210\/jc.2012-1169","article-title":"Skeletal-related events due to bone metastases from differentiated thyroid cancer","volume":"97","author":"Farooki","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026041705523867500_bvag065-B18","first-page":"3279","article-title":"Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems","volume":"21","author":"Oster","year":"2013","journal-title":"Support Care Cancer"},{"issue":"8","key":"2026041705523867500_bvag065-B19","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1097\/RLU.0000000000002626","article-title":"Thyroid cancer bone metastasis: survival and genomic characteristics of a large tertiary care cohort","volume":"44","author":"Kondraciuk","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"4","key":"2026041705523867500_bvag065-B20","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1210\/jcem.86.4.7390","article-title":"Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas","volume":"86","author":"Bernier","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026041705523867500_bvag065-B21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1089\/thy.2018.0582","article-title":"Improved survival after multimodal approach with 131I treatment in patients with bone metastases secondary to differentiated thyroid cancer","volume":"29","author":"Wu","year":"2019","journal-title":"Thyroid"},{"issue":"7","key":"2026041705523867500_bvag065-B22","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00259-022-05697-w","article-title":"Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival","volume":"49","author":"Jannin","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2026041705523867500_bvag065-B23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s002590000420","article-title":"Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age","volume":"28","author":"Petrich","year":"2001","journal-title":"Eur J Nucl Med"},{"issue":"10","key":"2026041705523867500_bvag065-B24","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1210\/jc.2011-0093","article-title":"Efficacy and survival analysis of 131 I therapy for bone metastases from differentiated thyroid cancer","volume":"96","author":"Qiu","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026041705523867500_bvag065-B25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12020-013-0123-8","article-title":"Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies","volume":"47","author":"Robenshtok","year":"2014","journal-title":"Endocrine"},{"key":"2026041705523867500_bvag065-B26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody","volume":"76","author":"von Moos","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"2026041705523867500_bvag065-B27","doi-asserted-by":"crossref","first-page":"115735","DOI":"10.1016\/j.bone.2020.115735","article-title":"Pharmacologic management of metastatic bone disease","volume":"158","author":"Schwartz","year":"2022","journal-title":"Bone"},{"issue":"12","key":"2026041705523867500_bvag065-B28","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"12","key":"2026041705523867500_bvag065-B29","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1054\/bjoc.2001.1832","article-title":"Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer","volume":"84","author":"Vitale","year":"2001","journal-title":"Br J Cancer"},{"issue":"1","key":"2026041705523867500_bvag065-B30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/thy.2010.0169","article-title":"Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma","volume":"21","author":"Orita","year":"2011","journal-title":"Thyroid"},{"issue":"12","key":"2026041705523867500_bvag065-B31","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1245\/s10434-015-4497-0","article-title":"Prospective evaluation of Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma","volume":"22","author":"Orita","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2026041705523867500_bvag065-B32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000493190","article-title":"The impact of Zoledronic acid and radioactive iodine therapy on Morbi-mortality of patients with bone metastases of thyroid cancer derived from follicular cells","volume":"8","author":"Andrade","year":"2019","journal-title":"Eur Thyroid J"},{"key":"2026041705523867500_bvag065-B33","first-page":"e12541","article-title":"Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours","volume":"26","author":"Zheng","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"2026041705523867500_bvag065-B34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12020-017-1455-6","article-title":"Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience","volume":"59","author":"Mazziotti","year":"2018","journal-title":"Endocrine"},{"issue":"52","key":"2026041705523867500_bvag065-B35","doi-asserted-by":"crossref","first-page":"90308","DOI":"10.18632\/oncotarget.19856","article-title":"Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2026041705523867500_bvag065-B36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of Longer-interval vs standard dosing of Zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"2026041705523867500_bvag065-B37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of Denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026041705523867500_bvag065-B38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of Denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026041705523867500_bvag065-B39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"15_suppl","key":"2026041705523867500_bvag065-B40","doi-asserted-by":"crossref","first-page":"e17578","DOI":"10.1200\/JCO.2019.37.15_suppl.e17578","article-title":"Safety of denosumab in patients with refractory differentiated thyroid cancer and advanced medullary thyroid cancer","volume":"37","author":"Wassermann","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026041705523867500_bvag065-B41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"2026041705523867500_bvag065-B42","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s40618-021-01634-0","article-title":"Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates","volume":"44","author":"Lorusso","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2026041705523867500_bvag065-B43","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.ijom.2019.07.010","article-title":"Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib","volume":"48","author":"Mauceri","year":"2019","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"10","key":"2026041705523867500_bvag065-B44","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O\u2019Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2026041705523867500_bvag065-B45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EC-14-0119","article-title":"Bone metastases and skeletal-related events from neuroendocrine tumors","volume":"4","author":"Van Loon","year":"2015","journal-title":"Endocr Connect"},{"issue":"2","key":"2026041705523867500_bvag065-B46","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MPA.0000000000000267","article-title":"Bone metastases in well-to-moderately differentiated neuroendocrine tumors: a single institutional review from the Ohio state university medical center","volume":"44","author":"Kavecansky","year":"2015","journal-title":"Pancreas"},{"issue":"12","key":"2026041705523867500_bvag065-B47","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","author":"Riihim\u00e4ki","year":"2016","journal-title":"Int J Cancer"},{"issue":"1","key":"2026041705523867500_bvag065-B48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000457954","article-title":"Bone metastases in patients with neuroendocrine neoplasm: frequency and clinical, therapeutic, and prognostic relevance","volume":"106","author":"Scharf","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"8","key":"2026041705523867500_bvag065-B49","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1002\/cam4.2259","article-title":"Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: a single-center study","volume":"8","author":"Song","year":"2019","journal-title":"Cancer Med"},{"issue":"7-8","key":"2026041705523867500_bvag065-B50","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1159\/000504256","article-title":"Identification of areas for improvement in the management of bone metastases in patients with neuroendocrine neoplasms","volume":"110","author":"Lim","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2026041705523867500_bvag065-B51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12902-020-0525-6","article-title":"Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). an analysis of SEER data from 2010 to 2014","volume":"20","author":"Trikalinos","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"2026041705523867500_bvag065-B52","doi-asserted-by":"crossref","first-page":"102168","DOI":"10.1016\/j.ctrv.2021.102168","article-title":"Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: a systematic review and meta-analysis","volume":"94","author":"Garcia-Torralba","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"2026041705523867500_bvag065-B53","doi-asserted-by":"crossref","first-page":"e210568","DOI":"10.1530\/EC-21-0568","article-title":"Bone metastases from neuroendocrine tumors: clinical and biological considerations","volume":"11","author":"Scopel","year":"2022","journal-title":"Endocr Connect"},{"issue":"2","key":"2026041705523867500_bvag065-B54","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.hbpd.2024.07.001","article-title":"Characteristics and risk differences of different tumor sizes on distant metastases of pancreatic neuroendocrine tumors: a retrospective study in the SEER database","volume":"24","author":"Dong","year":"2025","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"3","key":"2026041705523867500_bvag065-B55","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s12020-019-01838-8","article-title":"The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice","volume":"64","author":"Alexandraki","year":"2019","journal-title":"Endocrine"},{"issue":"1","key":"2026041705523867500_bvag065-B56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","article-title":"The impact of 68 Ga-DOTATATE PET\/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom","volume":"57","author":"Skoura","year":"2016","journal-title":"J Nucl Med"},{"issue":"10","key":"2026041705523867500_bvag065-B57","doi-asserted-by":"crossref","first-page":"e70073","DOI":"10.1111\/jne.70073","article-title":"Impact on symptoms and survival of bone metastases in patients with small-intestinal neuroendocrine tumours","volume":"37","author":"Wedin","year":"2025","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"2026041705523867500_bvag065-B58","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0002-9343(85)90313-4","article-title":"The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease","volume":"79","author":"Ross","year":"1985","journal-title":"Am J Med"},{"issue":"5","key":"2026041705523867500_bvag065-B59","doi-asserted-by":"crossref","first-page":"101784","DOI":"10.1016\/j.beem.2023.101784","article-title":"Management of non-hepatic distant metastases in neuroendocrine neoplasms","volume":"37","author":"Lacalle-Gonz\u00e1lez","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2026041705523867500_bvag065-B60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026041705523867500_bvag065-B61","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with Bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2026041705523867500_bvag065-B62","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines\u2020","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"2026041705523867500_bvag065-B63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000508633","article-title":"Bone metastases in neuroendocrine tumors: molecular pathogenesis and implications in clinical practice","volume":"111","author":"Cives","year":"2021","journal-title":"Neuroendocrinology"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvag065\/67507174\/bvag065.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/5\/bvag065\/68103880\/bvag065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/5\/bvag065\/68103880\/bvag065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:52:48Z","timestamp":1776419568000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvag065\/8540109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,7]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvag065","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,25]]},"article-number":"bvag065"}}